Stabilis

Phenylephrine hydrochloride



Kaubanduslikud nimed erinevates maades

Fedalefrina	Argentiina
Fencel	India
Fenilefrina	Argentiina, Brasiilia, Hispaania, Tšiili
Fenylefrin	Island, Norra, Rootsi, Soome, Taani
Frenin	India
Neosynephrine	Sloveenia
Phenylephrin	Belgia, Saksamaa, Sveits
Phenylephrine	Iraan, Kanada, Suurbritannia

Stabiilsus lahustes

PVC		0,1 & 0,2 mg/ml	25°C	?	14			1891
PP		0,1 mg/ml	-20°C		30			2194
PP		0,1 mg/ml	23-25°C		30			2194
PP		0,1 mg/ml	3-5°C		30			2194
?		0,02 mg/ml	2-8°C	?	24			3770
?		0,02 mg/ml	25°C	?	4			3770
?		0,1 mg/ml	2-8°C	?	24			3770
?		0,1 mg/ml	25°C	?	4			3770
?		0,02 mg/ml	2-8°C	?	24			3770
?		0,02 mg/ml	25°C	?	4			3770
?		0,1 mg/ml	2-8°C	?	24			3770
?		0,1 mg/ml	25°C	?	4			3770

Stabiilsust mõjutavad tegurid

?		2,5 mg/ml	25°C	?	Lidocaine hydrochloride : 20 mg/ml	66	1331

stabiilsust mõjutavad faktorid

	pH >7				3620

Sobimatus

		Phenylephrine hydrochloride : 0,04 mg/ml	Normo Sol®	4655
		Phenylephrine hydrochloride : 0,01 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Phenylephrine hydrochloride	▲	3620
		Phenylephrine hydrochloride : 0.04 mg/ml Amiodarone hydrochloride : 4 mg/ml	▲	1036
		Phenylephrine hydrochloride : 0.04 mg/ml Amiodarone hydrochloride : 4 mg/ml	◆	1036
		Phenylephrine hydrochloride Amoxicillin sodium / clavulanic acid		3545
		Phenylephrine hydrochloride Angiotensin II	▲	4818
		Phenylephrine hydrochloride	◆	3620
		Phenylephrine hydrochloride : 1 mg/ml Anidulafungin : 0.5 mg/ml	◆	1982
		Phenylephrine hydrochloride : 10 mg/ml Argatroban : 1 mg/ml	▲	1964
		Phenylephrine hydrochloride : 10 mg/ml Bivalirudin : 5 mg/ml	◆	1944
		Phenylephrine hydrochloride : 10 mg/ml Bivalirudin : 5 mg/ml	▲	1944
		Phenylephrine hydrochloride : 1 mg/ml Caspofungin acetate : 0,7 mg/ml	▲	2247
		Phenylephrine hydrochloride : 1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	▲	4528
		Phenylephrine hydrochloride : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml	◆	3828
		Phenylephrine hydrochloride	NaH CO3	3620
		Phenylephrine hydrochloride : 1 mg/ml Bivalirudin : 5 mg/ml	◆	1713

		Phenylephrine hydrochloride : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Phenylephrine hydrochloride : 1 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Phenylephrine hydrochloride Dexmedetomidine		5042
		Phenylephrine hydrochloride : 0.04 mg/ml Dobutamine hydrochloride : 2 mg/ml		1041
		Phenylephrine hydrochloride : 1 mg/ml Doripenem : 5 mg/ml		2262
		Phenylephrine hydrochloride : 1 mg/ml Doripenem : 5 mg/ml		2262
		Phenylephrine hydrochloride : 1 mg/ml Eravacycline : 0,6 mg/ml		4434
		Phenylephrine hydrochloride : 10 mg/ml Etomidate : 2 mg/ml		319
		Phenylephrine hydrochloride : 0.02 mg/ml Famotidine : 0.2 mg/ml		398
		Phenylephrine hydrochloride : 1 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Phenylephrine hydrochloride : 1 mg/ml Fosfomycin : 30 mg/ml		4055
		Phenylephrine hydrochloride : 1 mg/ml Fosfomycin : 30 mg/ml		4055
		Phenylephrine hydrochloride : 0.64 mg/ml Furosemide : 4 mg/ml		2116
		Phenylephrine hydrochloride : 1 mg/ml Furosemide : 10 mg/ml		3210
		Phenylephrine hydrochloride : 0.64 mg/ml Furosemide : 4 mg/ml		2116
		Phenylephrine hydrochloride : 0.02 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml		403
		Phenylephrine hydrochloride : 1 mg/ml Hetastarch : 60 mg/ml		1721
		Phenylephrine hydrochloride : 0,2 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Phenylephrine hydrochloride Imipenem-Cilastatin / Relebactam		4809
		Phenylephrine hydrochloride : 0,2 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Phenylephrine hydrochloride Iron (polymaltose)		3620
		Phenylephrine hydrochloride : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Phenylephrine hydrochloride : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Phenylephrine hydrochloride : 1 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Phenylephrine hydrochloride : 10 mg/ml Levofloxacine : 5 mg/ml		1072
		Phenylephrine hydrochloride : 2.5 mg/ml Lidocaine hydrochloride : 20 mg/ml		1331

		Phenylephrine hydrochloride : 1 mg/ml Micafungin : 1.5 mg/ml		2108
		Phenylephrine hydrochloride : 0.2 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Phenylephrine hydrochloride : 10 mg/ml Paracetamol : 10 mg/ml		4742
		Phenylephrine hydrochloride Phenytoin sodium		3620
		Phenylephrine hydrochloride : 1 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Phenylephrine hydrochloride : 0.1 mg/ml Propofol : 10 mg/ml	∅	300
		Phenylephrine hydrochloride : 10 mg/ml Propofol : 2 mg/ml	∅	319
		Phenylephrine hydrochloride : 0.1 mg/ml Propofol		660
		Phenylephrine hydrochloride : 1 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Phenylephrine hydrochloride Sodium bicarbonate		3620
		Phenylephrine hydrochloride : 1 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Phenylephrine hydrochloride : 1 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Phenylephrine hydrochloride : 1 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Phenylephrine hydrochloride : 1 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Phenylephrine hydrochloride : 1 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Phenylephrine hydrochloride : 10 mg/ml Thiopental sodium : 25 mg/ml		319
		Phenylephrine hydrochloride : 0.04 mg/ml Vasopressin : 2 & 4 UI/ml		1801
		Phenylephrine hydrochloride : 1 mg/ml Zidovudine : 4 mg/ml		337

Manustamis viis

Viited

	tüüp	avaldamine
59	ajaleht	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.

299	ajaleht	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	ajaleht	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
319	ajaleht	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
337	ajaleht	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
398	ajaleht	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
403	ajaleht	Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1539-1541.
660	ajaleht	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
1036	ajaleht	Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041	ajaleht	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1072	ajaleht	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1331	ajaleht	Das Gupta V, Steward KR. Chemical stabilities of lignocaine hydrochloride and phenylephrine hydrochloride in aqueous solution. J Clin Hosp Pharm 1986 ; 11 : 449-452.
1625	ajaleht	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1713	ajaleht	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	ajaleht	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1801	ajaleht	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803	ajaleht	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.

1891	ajaleht	Gupta VD. Chemical stability of phenylephrine hydrochloride after reconstitution in 0.9% sodium chloride injection for infusion. Int J Pharm Compound 2004 ; 8, 2: 153-155.
1944	ajaleht	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1964	ajaleht	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1982	ajaleht	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108	ajaleht	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2116	ajaleht	Faria CE, Fiumara K, Patel N, Tran DC. Visual compatibility of furosemide with phenylephrine and vasopressine. Am J Health-Syst Pharm 2006 ; 63: 906-908.
2194	ajaleht	Kiser TH, Oldland AR, Fish DN. Stability of phenylephrine hydrochloride injection in polypropylene syringes. Am J Health-Syst Pharm 2007 ; 64, 10: 1092-1095.
2247	ajaleht	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	ajaleht	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3152	ajaleht	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3210	ajaleht	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3254	ajaleht	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3545	Labor	Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009
3620	Labor	Phenylephrine - Summary of Product Characteristics Beacon Pharmaceuticals 2012
3770	Labor	Phenylephrine hydrochloride (Vazculep®) - Summary of Product Characteristics Eclat Pharmaceuticals 2014
3824	ajaleht	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	plakat	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015

3828	plakat	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	plakat	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	ajaleht	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	ajaleht	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433	ajaleht	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	ajaleht	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	ajaleht	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4655	ajaleht	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33
4742	ajaleht	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	ajaleht	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4809	Labor	Recarbrio® - Résumé des caractéristiques du produit 2024
4818	Labor	Giapreza 2.5mg per ml concentrate for solution for infusion - Summary of Product Characteristics Updated 30-Jun-2022 PAION UK Ltd 2022
5042	Labor	Dexdor 100 micrograms/ml concentrate for solution for infusion - Summary of Product Characteristics. Orion Corporation 2016

Stabilis

Phenylephrine hydrochloride



Stabiilsust ravimpreparaadid

	200 mg	Naatriumfosfaat 2 mg NaCl 0.9% 3,75 ml süstevesi >> 10 ml	20-25°C		60			3669

Stabiilsust mõjutavad tegurid

		25°C		Tropicamide : Lahus Mydriaticum® 5 mg/mL	90	3817
?	vesinikkloriidhape 0,1N > pH 4.2-5.8	2-8°C	?	Tropicamide : Kommertsravim Tropicamide USP 1% Bausch Lomb 7 Cyclopentolate : Kommertsravim Cyclopentolate USP 1% Bausch Lomb 7,5 mL	60	4111
?	vesinikkloriidhape 0,1N > pH 4.2-5.8	2-8°C	?	Tropicamide : Kommertsravim Tropicamide USP 1% Bausch Lomb 1	60	4111

Viited

	tüüp	avaldamine
3669	ajaleht	Dreno C, Gicquel T, Harry .M, Tribut O, Aubin F, Brandhonneur N, Dollo G. Formulation and stability study of a pediatric 2% phenylephrine hydrochloride eye drop solution Ann Pharm Fr 2015 ; 73, 1: 31-36.
3817	plakat	Stordeur F, Chanat C, Brandely M.L, Chast F. A stability study of 25 mg/mL phenylephrine hydrochloride and 5 mg/mL tropicamide eye drops. Gerpac Congress, Giens, France 2015

4111	ajaleht	Camp N, Nadra J, Hughes S, Gilbert J, Zhao F. Stability of extemporaneously prepared ophtalmic solutions for mydriasis. Am J Health-Syst Pharm 2018 ;75,9:231-235

Sõnaraamat

	sümpatomimeetikum
	Kaubanduslikud nimed erinevates maades
	konteiner
	kontsentratsioon
	ladustamine
	biosimilar
	Viited
	naatriumkloriid 0.9%
	päev
	kaitsta valguse eest
?	pole täpsustatud
	glükoos 5%
	lahusti
	apürogeenne vesi
	indutseerib
	Sobimatus
	Sobimatu
	Ühilduv
NaH CO3	NaHCO3
	Kohene sade
	Sade 4 tunni pärast
RL	Ringer laktaat
	Manustamis viis
	intravenoosne infusioon
	intramuskulaarne
	Viited
	Stabiilsust ravimpreparaadid
	abiaine
	pulber
	Sõnaraamat

	Süsteravim
	Stabiilsus lahustes
	Molekul
	temperatuur
	Stabiilsuse kestus
	vastuolulisi andmeid
PVC	polüvinüülkloriid
?	pole täpsustatud
	süstal polüpropüleenist
	valgus
	Tund
	Stabiilsust mõjutavad tegurid
	ingredient
	stabiilsust mõjutavad faktorid
	degradatsioon
	Kohene hägusus
Normo Sol®	Normosol®
	Täpsustamata sobimatus
∅	mitte ükski
	konkreetsed lahusti
	Emulsiooni ebastabiilsus 6 tunni pärast
	süstevesi
	intravenoosne
	pidevinfusioon
	subkutaanne
	Silmatilgad
	Origine
	klaas
	Plastikpudel